title: T cell receptor (TCR) signal strength controls arthritis severity in proteoglycan-specific TCR transgenic mice.
abstract: T cell receptor transgenic (TCR-Tg) mice specific for the arthritogenic 5/4E8 epitope in the G1 domain of cartilage proteoglycan were generated and back-crossed into arthritis-prone BALB/c background. Although more than 90% of CD4(+)  T cells of all TCR-Tg lines were 5/4E8-specific, one (TCR-TgA) was highly sensitive to G1-induced or spontaneous arthritis, while another (TCR-TgB) was less susceptible. Here we studied whether fine differences in TCR signalling controlled the onset and severity of arthritis. Mice from the two TCR-Tg lines were immunized side by side with purified recombinant human G1 (rhG1) domain for G1 domain of cartilage proteoglycan (PG)-induced arthritis (GIA). TCR-TgA mice developed severe and early-onset arthritis, whereas TCR-TgB mice developed weaker arthritis with delayed onset, although TCR-TgB CD4(+)  T cells expressed approximately twice more TCR-Vβ4 chain protein. The more severe arthritis in TCR-TgA mice was associated with higher amounts of anti-G1 domain-specific antibodies, larger numbers of B cells and activated T helper cells. Importantly, TCR-TgB CD4(+)  T cells were more sensitive to in vitro activation-induced apoptosis, correlating with their higher TCR and CD3 expression and with the increased TCR signal strength. These findings indicate that TCR signal strength determines the clinical outcome of arthritis induction: 'optimal' TCR signal strength leads to strong T cell activation and severe arthritis in TCR-TgA mice, whereas 'supra-optimal' TCR signal leads to enhanced elimination of self-reactive T cells, resulting in attenuated disease.
authors.affiliation: Section of Molecular Medicine, Department of Orthopedic Surgery, Rush University Medical Center, Chicago, IL, USA.
authors.forename: K
authors.initials: K
authors.lastname: Olasz
authors.forename: F
authors.initials: F
authors.lastname: Boldizsar
authors.forename: K
authors.initials: K
authors.lastname: Kis-Toth
authors.forename: O
authors.initials: O
authors.lastname: Tarjanyi
authors.forename: A
authors.initials: A
authors.lastname: Hegyi
authors.forename: W
authors.initials: W
authors.lastname: van Eden
authors.forename: T A
authors.initials: TA
authors.lastname: Rauch
authors.forename: K
authors.initials: K
authors.lastname: Mikecz
authors.forename: T T
authors.initials: TT
authors.lastname: Glant
mesh_terms: D053674:Aggrecans / Q000276:immunology; D000595:Amino Acid Sequence; D000818:Animals; D017209:Apoptosis; D001169:Arthritis, Experimental / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000473:pathology; D002358:Cartilage, Articular / Q000276:immunology; D004195:Disease Models, Animal; D004198:Disease Susceptibility / Q000276:immunology; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D018628:Gene Dosage; D006801:Humans; D007114:Immunization; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D010766:Phosphorylation; D011499:Protein Processing, Post-Translational; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D011509:Proteoglycans / Q000276:immunology*; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000235:genetics / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology
chemical_list: D053674:Aggrecans; D018984:Epitopes, T-Lymphocyte; D011509:Proteoglycans; D016693:Receptors, Antigen, T-Cell, alpha-beta; D011994:Recombinant Proteins; D011505:Protein-Tyrosine Kinases